Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBG002
- Development stage
- Preclinical
- Lead developer
- Sonoran Biosciences
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Local
01
Overview
SBG002 is an investigational, extended-release antibiotic formulation developed by Sonoran Biosciences for the prevention and treatment of serious orthopaedic infections, including surgical site infections (SSI), osteomyelitis, and periprosthetic joint infections (PJI). The product utilizes Sonoran's proprietary SB Gel technology, a liquid-to-solid phase-changing hydrogel that is applied locally during surgery. Once applied, the viscous liquid solidifies into a gel that provides sustained release of vancomycin directly at the site of potential infection for several days. This localized delivery achieves high therapeutic concentrations of the antibiotic to eradicate bacteria and biofilms while maintaining low systemic exposure, thereby reducing the risk of systemic toxicities such as nephrotoxicity. SBG002 is currently in the IND-enabling and preclinical stages of development.
- Other names
- SB Gel vancomycin
02
Targets
Bacterial RibosomeD-alanyl-D-lactate peptidoglycan precursorMT-RNR1 (Mitochondrially encoded 12S ribosomal RNA)D-Ala-D-Ala (D-Ala-D-Ala terminus)TA (Teichoic acid)
Beyond the preview
Go deeper on SBG002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBG002.